Congress Weighs Who Should Have the ‘Right To Try’

There is renewed energy around a policy that would allow seriously ill patients access to experimental therapies, but lawmakers are debating who should be given this benefit.

Sen. Ron Johnson attends a Senate Governmental Affairs subcommittee hearing on international mail and the opioid crisis Jan. 25.
AP Photo/Jacquelyn Martin
Feb. 7, 2018, 8 p.m.

President Trump infused momentum into policy that would allow terminally ill patients quick access to experimental medication, but lawmakers are still working out how many patients should be given this choice.

The promise to circumvent bureaucracy in order to save the lives of the terminally ill will likely sound appealing to voters. Turning Trump’s endorsement into policy, however, won’t be an easy task for lawmakers—even if they generally support the idea.

Sen. Ron Johnson, who championed a right-to-try bill through the Senate, said Trump’s endorsement in the State of the Union sparked momentum around the issue. Johnson added that he is having discussions with House Republican leaders about moving the bill forward. On Monday, 42 lawmakers also wrote to House Speaker Paul Ryan and House Majority Leader Kevin McCarthy asking that Johnson’s bill be brought to the floor.

“This bill safeguards any pharmaceutical company that may wish to participate in Right to Try, but it in no way requires participation to begin with. We are not seeking to impose a mandate on anyone. Instead, we are merely seeking to give patients who have no other options yet another possibility to try to save their own lives,” they wrote.

But policy differences are likely to arise, particularly around how expansive the effects of the legislation should be.

This issue was raised in October when Food and Drug Administration Commissioner Scott Gottlieb appeared before the Energy and Commerce Committee on the topic. He said the Senate version of right-to-try could allow more patients than intended access to investigational products, and recommended narrowing the eligibility from patients who face a “life-threatening disease or condition” to those with a “terminal illness.”

“Many chronic conditions are life-threatening, but medical and behavioral interventions make them manageable without recourse to unapproved therapies,” he told lawmakers in his written testimony.

Johnson expressed concern that changes to the legislation would limit the number of people who could benefit. “I want to make sure that it maintains the freedom for as many individuals in that situation as possible; I don’t want to limit the number of Americans who can take advantage of that,” he told National Journal. “Some of the tweaks I think would dramatically limit it. I mean, for example, maybe a young boy with Duchenne muscular dystrophy could be narrowed out of that definition, which I think would be a real shame.”

But energy committee Chairman Greg Walden said they are looking to improve the bill. “We’re very close on language that will make it even better and a more usable bill,” he said, adding that they are looking at who would benefit from the legislation.

“Remember, this is for terminally ill patients, I mean that’s what we’re told. The language that came over from the Senate says people with incurable diseases, so that would include things like rheumatoid arthritis, diabetes … We’re looking at a lot of those issues,” said Walden.

The right-to-try initiative, backed by the libertarian Goldwater Institute, began at the state level. According to the institute, 38 states have passed laws aiming to cut the red tape around experimental therapies that could help seriously ill patients.

In the process, however, it would also sidestep FDA protections. The FDA has asserted that it already has the ability to quickly bring unapproved medicines to ill patients through the expanded access pathway. Expanded access, or compassionate use, is for patients who are seriously ill and cannot enroll in a clinical trial. The agency says it authorizes 99 percent of these requests, but it cannot require the companies making the therapy to participate.

The Goldwater Institute argues that this process is not working. “[A]n investigation by the Goldwater Institute shows that the entire system for gaining access to an unapproved medication is so rigged with bureaucracy and disincentives that it is bound to fail in most cases,” the group states on its website.

But according to a spate of patient-advocacy groups, the barrier is typically the company denying the request. “When access to a therapy is denied to a patient, it is generally the company that denies the request, and for reasons that appear to be reasonable, such as a determination that the benefits do not outweigh the risks, an unavailability of sufficient product to offer outside of clinical trials, costs, or concerns about adversely affecting clinical trial enrollment,” the groups wrote in a letter to House leaders Tuesday urging against Johnson’s legislation.

The issue moved to the national level when the legality of these state laws were called into question. Johnson has told the FDA in the past that his legislation would clear up these uncertainties.

“It would clarify that the federal government cannot prohibit doctors from treating terminal patients in accordance with state law if certain requirements are met,” he wrote to the agency in a 2016 letter. “The bill includes liability protections for doctors and manufacturers who provide treatment under federal and state right to try laws. It also requires that the FDA not use adverse outcomes of treatments used under right to try laws when reviewing extant Investigational New Drug applications.”

Now, the president has generally backed the idea, naming Gottlieb as the person who would lead this initiative.

“So important—right-to-try. You know, those drugs, they sit in there for 12, 13, 14 years. And a person is terminally ill, they have two months left, and under the old system they don’t want to give them even an experimental medicine because they’re afraid they’re going to be hurt. Well, they’re not going to be around for two months,” the president told GOP lawmakers at their retreat last week.

What We're Following See More »
POLIQUIN STILL CHALLENGING RANKED-CHOICE VOTING
Poliquin Loses in Maine's 2nd District
10 hours ago
THE LATEST

"Democrat Jared Golden has defeated Maine Rep. Bruce Poliquin in the nation’s first use of ranked-choice voting for a congressional race, according to state election officials. The Democrat won just over 50 percent of the vote in round one of ranked-choice voting, meaning he’ll be the next congressman from the 2nd District unless Poliquin’s legal challenges to the voting system prevail. A Golden win in the 2nd District, which President Donald Trump carried in 2016, mean Democrats have picked up 35 seats in the House."

Source:
IF SHE AGREES TO RULES REFORMS
Republicans Could Back Pelosi in Speaker Vote
10 hours ago
THE LATEST

"Rep. Tom Reed (R-N.Y.) said he and some other Republicans are committed to backing Nancy Pelosi (D-Calif.) for Speaker if she agrees to enact a package of rule reforms. Reed, co-chair of the bipartisan Problem Solvers Caucus, said the growing frustration with gridlock, polarization and a top-heavy leadership approach in Congress are the reasons why several members in his party are willing to supply Pelosi with some Speaker votes in exchange for extracting an overhaul of the House rules." The caucus wants to fast-track any legislation with support of two-thirds of members, and require a supermajority to pass any legislation brought up under a closed rule.

Source:
FOUR TWEETS OVER THREE HOURS
Trump Lashes Out at Mueller Investigation
12 hours ago
THE LATEST
COULD MEMBERS PICK THEIR OWN CHAIRS?
House GOP May Change Method for Committee Assignments
1 days ago
THE LATEST

"House Republicans on Thursday will consider changes to their internal conference rules, with several amendments targeting the process for selecting committee leaders. The biggest proposed change comes from Wisconsin Rep. Mike Gallagher, who wants committee members to be able to choose their own chairmen or ranking members," rather than leadership or the steering committee.

Source:
COULD IMPACT RESULTS IN MAINE DISTRICT
Judge to Rule Thursday on Ranked-Choice Voting
1 days ago
THE LATEST
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login